The FDA ordered a black-box warning for Salix Pharmaceuticals' Visicol and OsmoPrep to alert consumers about the risk of kidney injury from the oral sodium phosphate drugs. The warning is intended for patients older than 55, people who are dehydrated or have kidney disorders and individuals who use medicines that affect kidney function.

Related Summaries